Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lol

<< Previous

Bullboard Posts

Next >>

Post by Rarbar99on Aug 19, 2021 2:03pm

341 Views

Post# 33731394

Lol

I'm done replying to Inthepez, just check his profile this kids been talking trash to bears for several months. Even after this dropped 70% he still refuses to listen to criticism and calls everything "fud"

fact of the matter is that this is in very bad shape. The volume is already gone, everything from here is unpredictable. It's just as likely to go to $0.75 as it is $1.50.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks